Company news
Omeros Corporation news in 2024
Omeros Corporation's news releases, calls and decks from 2024, newest first.
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
December 18, 2024
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting
December 9, 2024
Omeros Corporation Provides Update on Progress Toward BLA Resubmission
November 20, 2024
Omeros Corporation Reports Third Quarter 2024 Financial Results
November 12, 2024
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024
November 10, 2024
FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy
October 23, 2024
Omeros Corporation Reports Second Quarter 2024 Financial Results
August 6, 2024
Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028
June 2, 2024
Omeros Corporation Reports First Quarter 2024 Financial Results
May 14, 2024
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024
May 9, 2024
Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress
May 8, 2024
Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results
March 31, 2024
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024
March 26, 2024
Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
February 19, 2024
Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust
January 31, 2024